Jang Ho Cho

1.1k total citations
29 papers, 645 citations indexed

About

Jang Ho Cho is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jang Ho Cho has authored 29 papers receiving a total of 645 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Jang Ho Cho's work include Lung Cancer Treatments and Mutations (12 papers), Gastric Cancer Management and Outcomes (9 papers) and Lung Cancer Research Studies (7 papers). Jang Ho Cho is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Gastric Cancer Management and Outcomes (9 papers) and Lung Cancer Research Studies (7 papers). Jang Ho Cho collaborates with scholars based in South Korea and United States. Jang Ho Cho's co-authors include Jin Seok Ahn, Keunchil Park, Se‐Hoon Lee, Myung‐Ju Ahn, Jong‐Mu Sun, Eun Joo Kang, Keon Uk Park, Ho Jung An, Yoon Hee Choi and Ki Hwan Kim and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Analytical Chemistry.

In The Last Decade

Jang Ho Cho

27 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jang Ho Cho South Korea	12	462	427	174	131	62	29	645
Maria Rosa Cappelletti Italy	13	251 0.5×	312 0.7×	213 1.2×	239 1.8×	34 0.5×	32	635
Jurjen J. Boonstra Netherlands	14	322 0.7×	367 0.9×	205 1.2×	121 0.9×	348 5.6×	49	781
S-H.I. Ou United States	9	515 1.1×	372 0.9×	140 0.8×	93 0.7×	33 0.5×	34	642
Jeanne Fourie Zirkelbach United States	11	218 0.5×	267 0.6×	122 0.7×	104 0.8×	42 0.7×	14	557
Chihiro Dohi Japan	12	132 0.3×	285 0.7×	168 1.0×	301 2.3×	91 1.5×	17	502
Simona Aloe Italy	12	94 0.2×	244 0.6×	159 0.9×	94 0.7×	52 0.8×	16	448
A Fujioka Japan	7	344 0.7×	506 1.2×	170 1.0×	80 0.6×	130 2.1×	16	680
Bavanthi Balakrishnar Australia	10	186 0.4×	195 0.5×	160 0.9×	114 0.9×	17 0.3×	25	469
Christa G.M. Gadellaa-van Hooijdonk Netherlands	6	121 0.3×	349 0.8×	106 0.6×	141 1.1×	30 0.5×	7	506

Countries citing papers authored by Jang Ho Cho

Since Specialization

Citations

This map shows the geographic impact of Jang Ho Cho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jang Ho Cho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jang Ho Cho more than expected).

Fields of papers citing papers by Jang Ho Cho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jang Ho Cho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jang Ho Cho. The network helps show where Jang Ho Cho may publish in the future.

Co-authorship network of co-authors of Jang Ho Cho

This figure shows the co-authorship network connecting the top 25 collaborators of Jang Ho Cho. A scholar is included among the top collaborators of Jang Ho Cho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jang Ho Cho. Jang Ho Cho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Young Saing, Keon Uk Park, Jang Ho Cho, et al.. (2024). Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18. JTO Clinical and Research Reports. 5(12). 100734–100734. 1 indexed citations

Kim, Hong-Sik, Dong‐Wan Kim, Miso Kim, et al.. (2021). Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11). Cancer. 128(4). 778–787. 30 indexed citations

Byeon, Seonggyu, Jang Ho Cho, Hyun Ae Jung, et al.. (2020). PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence. Cancer Medicine. 9(7). 2352–2362. 32 indexed citations

Cho, Jang Ho, Sun Young Kim, Sun Young Kim, et al.. (2020). Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer. Journal of Cancer Research and Therapeutics. 17(4). 1047–1051. 5 indexed citations

Kim, Hee Kyung, Soo Hyun Lee, Yu Jin Kim, et al.. (2019). Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. BMC Cancer. 19(1). 84–84. 7 indexed citations

Cho, Jang Ho, Ju Sun Kim, Seung Tae Kim, et al.. (2019). Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. PLoS ONE. 14(4). e0215080–e0215080. 3 indexed citations

Cho, Jang Ho, Sun Young Kim, Jeeyun Lee, et al.. (2019). Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. Translational Cancer Research. 8(5). 2107–2112. 2 indexed citations

Cho, Jang Ho, Hyun Ae Jung, Se‐Hoon Lee, et al.. (2019). Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. Journal of Cancer Research and Clinical Oncology. 145(5). 1341–1349. 17 indexed citations

Byeon, Seonggyu, Youjin Kim, Sung Won Lim, et al.. (2018). Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. Cancer Research and Treatment. 51(2). 623–631. 37 indexed citations

10.

Lim, Sung Won, Sehhoon Park, Youjin Kim, et al.. (2018). Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. Lung Cancer. 124. 293–297. 11 indexed citations

11.

Ahn, Myung‐Ju, Jang Ho Cho, Jong‐Mu Sun, et al.. (2018). An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).. Journal of Clinical Oncology. 36(15_suppl). 9050–9050. 16 indexed citations

12.

Kim, Hee Kyung, Kyung Hee Park, Youjin Kim, et al.. (2018). Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. Cancer Research and Treatment. 51(2). 737–747. 51 indexed citations

13.

Cho, Jang Ho, et al.. (2017). Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS ONE. 12(10). e0186362–e0186362. 13 indexed citations

14.

Cho, Jang Ho, Bo Mi Ku, Jong‐Mu Sun, et al.. (2017). KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. Journal of Thoracic Oncology. 13(3). e29–e31. 32 indexed citations

15.

Cho, Jang Ho, Jae Yun Lim, & Y. Choi. (2017). Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. World Journal of Gastroenterology. 23(41). 7407–7414. 11 indexed citations

16.

Lim, Jae Yun, Jang Ho Cho, Se Joon Lee, et al.. (2015). Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. 47(2). 266–273. 3 indexed citations

17.

Cho, Jang Ho, Jae Yun Lim, Y. Choi, et al.. (2015). Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with krukenberg tumor. 47(4). 697–705. 2 indexed citations

18.

Lim, Jae Yun, Jang Ho Cho, Se Joon Lee, et al.. (2014). Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Research and Treatment. 47(2). 266–273. 10 indexed citations

19.

Cho, Jang Ho, Jae Yun Lim, Sung Min Choi, et al.. (2014). Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. Cancer Research and Treatment. 47(4). 697–705. 36 indexed citations

20.

Kim, Hae Won, Jang Ho Cho, Kyoung Hwa Lee, et al.. (2013). A Case Of Pancreaticoduodenal Aneurysm Diagnosed By Endoscopic Ultrasound Before Rupture. 18(4). 29–33.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact